Indeed, AR and ESR1 were identified as the targets of the sex hormones testosterone and estradiol, respectively, whereas HDACs and BRDs were suppressed upon treatment with the anti-tumor drugs vorinostat and JQ1. Here, AR is linked to neoplasm.